OptiNose stock surges 53% as it is set to be acquired by Paratek for $330 million, adding chronic rhinosinusitis drug, Xhance, to the latter's portfolio.
Small-Cap Firms Dominate Thursday’s Gains. In this article, we are going to take a look at where OptiNose Inc. (NASDAQ:OPTN) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback